Economia
ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America
ALK (ALKB:DC / OMX: ALK B) today announced the appointment of Edward Jordan as new Executive Vice President (EVP) and head of Commercial Operations in North America as per 5 January 2026. Edward Jordan succeeds Søren Niegel who has temporarily assumed the position following the decision, effective 1 October 2025, to elevate ALK’s two key commercial regions, Europe and North America. into the Executive Leadership Team (ELT) to further strengthen the execution of ALK’s strategy.
Edward Jordan, an American citizen, brings more than 30 years of biopharmaceutical experience, including roles at Merck (Schering-Plough), Teva Pharmaceuticals, and DBV Technologies, deep expertise in allergy and immunology, comprising work on Claritin, Clarinex, and Viaskin, as well as knowledge of the emerging food allergy market. With a strong track record in US commercial strategy, product launches, and market development, Edward Jordan has built therapeutic markets, established European and Scandinavian companies in the USA, and advanced therapies that improve patient outcomes. He holds an MBA from Southern New Hampshire University and dual bachelor’s degrees in finance and insurance from the University of Rhode Island.
President & CEO Peter Halling said: “T
Edward Jordan said:
Following the appointment, ALK’s Executive Leadership Team consists of:
Investor Relations : Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
: Maiken Riise Andersen, tel. +45 5054 1434
Attachment
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti